|Bid||75.06 x 1800|
|Ask||0.00 x 1200|
|Day's range||74.55 - 76.25|
|52-week range||52.83 - 76.25|
|Beta (3Y monthly)||0.60|
|PE ratio (TTM)||156.82|
|Earnings date||31 Jan 2019 - 4 Feb 2019|
|Forward dividend & yield||2.20 (2.94%)|
|1y target est||79.12|
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Attractive stocks have exceptional fundamentals. In the case of Merck & Co Inc (NYSE:MRK), there’s is a company with a an impressive history of dividend payments as well as a Read More...
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
Merck (MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.
Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.
AstraZeneca and Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019.
Approval Marks 14th Indication for KEYTRUDA
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Stu